SCROLL DOWN
A company that realizes a healthy life for mankind
through continuous challenges and active investment
-
PANGEN BIOTECH
The platform patented technology, a stable and fast growing biopharmaceutical company
-
R&D
Developing global biosimilar products by utilizing platform patented technology for establishing production cell lines and biopharmaceutical product commercialization technology
-
ACHIEVEMENTS
Approval of biosimilar EPO product GMP re-certification of biopharmaceutical manufacturing plant
PanGen Biotech
Disclosures & ir news
PanGen's disclosure information and stocks information
-
Disclosures
Outcomes of Extraordinary General Meeting of Shareholders
2025.09.26
-
Disclosures
Resolutions for Convocation of General Meeting of Shareholders(임시주주총회)
2025.08.20
-
Disclosures
Additional Listing(유상증자(제3자배정))
2025.05.28
-
Disclosures
Results of issuance(Voluntary Disclosure)
2025.05.12
-
Disclosures
Decision on Paid-in Capital Increase(제3자배정)
2025.05.02
-
Disclosures
Contract for Sales or Supply
2025.04.02
-
Notice
PanGen Biotech Reports Q3 2025 Results, Cumulative Sales of 10.94 Billion Won, Operating Profit of 1.91 Billion Won
2025.11.13
-
Notice
PanGen Biotech to Renew its GMP Certification in Turkiye
2025.09.25
-
Notice
PanGen Biotech Reports Q2 2025 Financial Results with 3.49 Billion won in Revenue and 833 million won in Profit
2025.08.13
-
Notice
PanGen posts Q1 sales of 3.4 billion won and operating profit of 700 million won
2025.05.14
Promotional video
Huons, Global Total Healthcare Group
Presenting Medical Solutions for Human Health
CS CENTER